by Gaucher disease is the most common lysosomal storage disorder caused due to the deficiency of glucocerebrosidase enzyme that leads to the excess build-up of lipid globotriosylceramide (glucosylceramide) in macrophage system cells. Enzyme replacement therapies (ERTs) such as imiglucerase, velaglucerase alfa, and taliglucerase alfa as well as substrate reduction therapy, are the major treatment options for Gaucher disease.
The global gaucher disease treatment market is estimated to be valued at US$ 2.0 billion in 2024 and is expected to exhibit a CAGR of 2.7% over the forecast period 2024 to 2030.
Key Takeaways
Key players operating in the gaucher disease treatment market are Sanofi, Takeda Pharmaceutical Company Limited, Pfizer Inc, Johnson & Johnson Services, Inc., and ERAD Therapeutic. Sanofi’s Cerezyme is the most prescribed ERT for Gaucher disease treatment globally. However, Takeda’s Elelyso was the first plant cell-based therapy approved by the FDA in 2012.
The key opportunities in the gaucher disease treatment market include strengthening awareness about lysosomal storage disorders and orphan drug designation for developing novel treatment therapies. Several companies are engaged in research and development of small molecule chaperones and gene therapies to provide potential cures for Gaucher disease.
The global gaucher disease treatment market is estimated to witness high growth owing to increasing initiatives by governments and non-profit organizations to spread awareness about rare and orphan diseases. Expanding patient pool in emerging markets of Asia Pacific and Latin America also provides lucrative business opportunities.
Market Drivers
The major market driver for Gaucher Disease Treatment Market Growth is rising prevalence of lysosomal storage disorders globally. It is estimated that Gaucher disease affects around 1 in 57,000 to 1 in 100,000 live births worldwide. In addition, increasing approvals of pipeline drugs and strong research and development investments by pharmaceutical companies in developing novel treatment therapies are further fueling the market growth.
PEST Analysis
Political: Regulations play an important role in drug development and pricing of treatments. Favorable reimbursement policies by governments help increase access to expensive treatment options.
Economic: Healthcare spending has been increasing globally. Rising disposable incomes in developing nations also enhance patient affordability for costly therapies.
Social: Growing patient awareness regarding rare diseases and available treatment options via social media boosts demand. Support groups help patients cope up with the chronic condition.
Technological: Advancements in biologics like enzyme replacement therapies (ERT) help manage symptoms better. Stem cell therapies offer hope of a potential cure in future.
Geographical regions where market in terms of value is concentrated:
North America accounts for the largest share of the global market currently attributed to high treatment penetration and adoption of ERTs. Presence of favorable reimbursement policies aids region’s market dominance.
Fastest growing region for the Gaucher disease treatment market:
Asia Pacific region is anticipated to witness the highest growth over the forecast period owing to rising healthcare expenditures, growing patient population, and increasing economic prosperity in leading countries like China and India. Furthermore, improving access to advanced treatments also support market expansion in the region.
*Note:
1. Source: Coherent Market Insights, Public sources, Desk research
2. We have leveraged AI tools to mine information and compile it
